SLS and ATNM are heading into the AACR summit with fresh leukemia-focused data catalysts expected to refocus investor attention. ・Sellas will present preclinical AML data on SLS009, demonstrating ...
SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.
Sellas Life Sciences has surged over 250% since December 2025, driven by positive clinical data for its AML therapies. Learn ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DataVisor, a stand-out provider of AI-powered fraud and financial crime prevention solutions, has been recognized as a Leader, the report’s highest designation, ...
The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results